insulin aspart
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | FIASP PENFILL | — | 2019-10-21 – 2019-12-19 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | NOVOLOG PENFILL | — | 2001-12-21 – 2015-01-14 | fda.gov ↗ |
| Approved | US (FDA) | NOVOLOG PENFILL | — | 2000-06-07 | fda.gov ↗ |
| Approved | EU (EMA) | NovoRapid | — | 1999-09-07 | europa.eu ↗ |
Trials 166 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06547619 | Oct 2024 → May 2026 overdue | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05946798 | Aug 2023 → Jun 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05946785 | Jul 2023 → Dec 2026 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT03666065 | Jan 2020 → Jun 2023 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 141 trials | ||||||
| Phase 1 | NCT07341373 | Feb → Sep 2026 expected | type 1 diabetes mellitus | Portal Diabetes, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07068295 | Jul 2025 → Feb 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06809621 | Jan → Jul 2025 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06375031 | May → Jul 2024 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05737576 | Mar → Oct 2023 | diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05754424 | Feb 2023 → Jan 2024 | type 2 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
| Phase 1 | NCT05413863 | May → Dec 2022 | — | Biocon Limited | Completed | No outcome recorded |
| Phase 1 | NCT05184868 | Jan → Sep 2022 | type 1 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
| Phase 1 | NCT04660305 | Dec 2020 → Jun 2021 | type 1 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
| Phase 1 | NCT04237129 | Aug → Dec 2019 | type 1 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
| Phase 1 | NCT03959514 | Apr → Jul 2019 | type 1 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
| Phase 1 | NCT03436498 | May → Oct 2018 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03407599 | Jan → Jul 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03215498 | Jul → Nov 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02594033 | Oct 2015 → Jan 2016 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02462161 | Mar 2015 → Apr 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02089451 | Mar → Jun 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01992588 | Nov 2013 → Mar 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01934712 | Aug 2013 → Jan 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01773798 | Jan → Aug 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01590836 | Apr → Jun 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01399346 | Apr → Jun 2011 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 1 | NCT01269606 | Jan → Mar 2011 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01173926 | Jul → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01121276 | Apr → Sep 2010 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00979875 | Sep 2009 → Feb 2010 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01868568 | Apr → Aug 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01159353 | Sep 2007 → Apr 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01865305 | Sep 2006 → Feb 2007 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01536028 | Apr → Jul 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00115973 | Jun 2005 → Jan 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00184613 | May 2005 → Jan 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01620450 | Nov 2004 → Feb 2005 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01486914 | Jan → Feb 2003 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01698697 | Sep → Oct 2002 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00513643 | Apr → Jun 2002 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01526941 | May → Jul 2001 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01620424 | Feb → Apr 2001 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01620333 | Feb → Apr 2000 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01523041 | Nov 1999 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01707160 | Nov → Dec 1995 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00581867 | Oct 2007 → May 2012 | Alzheimer disease | Jeff Burns, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00353990 | Aug → Dec 2006 | diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06072963 | Jan 2024 → Dec 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, metabolic syndrome X | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT04542148 | Feb 2022 → Nov 2025 overdue | gestational diabetes, type 2 diabetes mellitus | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03800875 | Feb 2019 → Sep 2020 | type 1 diabetes mellitus | McGill University | Completed | No outcome recorded |
| Phase 2 | NCT04292535 | Jun 2018 → Feb 2020 | — | Michigan State University | Completed | No outcome recorded |
| Phase 2 | NCT01561378 | Aug 2012 → Oct 2014 | delirium, subjective cognitive decline | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01756105 | Jun 2012 → Feb 2018 | gestational diabetes | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 2 | NCT01510093 | May → Dec 2012 | type 2 diabetes mellitus | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01194245 | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01194258 | Aug 2010 → Aug 2011 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00764556 | May 2008 → May 2009 | chronic obstructive pulmonary disease, hyperglycemia | St George's, University of London | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT03262116 | Mar → Jul 2019 | type 1 diabetes mellitus | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT03565666 | Jul → Nov 2018 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02496780 | Aug 2015 → Jul 2022 | cystic fibrosis | University of Minnesota | Terminated | No outcome recorded |
| Phase 2/3 | NCT02101229 | May 2014 → Feb 2015 | type 1 diabetes mellitus | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | Completed | No outcome recorded |
| Phase 334 trials | ||||||
| Phase 3 | NCT05802862 | Jul 2023 → Aug 2024 | diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05641337 | Oct 2022 → Dec 2025 | cirrhosis of liver, diabetes mellitus | Huashan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04460326 | Dec 2020 → May 2023 | type 2 diabetes mellitus | Boston Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03977727 | Jun 2019 → Mar 2020 | type 1 diabetes mellitus | Texas Diabetes & Endocrinology, P.A. | Completed | No outcome recorded |
| Phase 3 | NCT04079413 | Jun 2019 → Jan 2020 | type 1 diabetes mellitus | Geropharm | Completed | No outcome recorded |
| Phase 3 | NCT03874715 | Mar 2019 → Jul 2020 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02500706 | May 2016 → Jul 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02546401 | Sep 2015 → Mar 2016 | type 1 diabetes mellitus | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT02491528 | Jun 2015 → Aug 2016 | diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01850615 | Sep 2013 → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01819129 | Sep 2013 → Jan 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01814137 | Mar 2013 → Mar 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01713530 | Feb 2013 → Jan 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01388361 | Sep 2011 → Jul 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00888732 | Jun 2009 → Jun 2010 | type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00314314 | May 2006 → Mar 2009 | bipolar disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT00267683 | Dec 2005 → Apr 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00151697 | May 2005 → ? | type 2 diabetes mellitus | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00097877 | Jan 2005 → Nov 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00097071 | Oct 2004 → May 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00500240 | Apr 2004 → Apr 2012 | acute leukemia, lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT00600626 | Jan → Jul 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00605020 | Dec 2003 → Mar 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00604656 | May 2003 → Jan 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00725036 | Sep 2002 → Dec 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00071448 | Jun 2002 → Jun 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01486940 | Mar → Oct 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01650129 | Dec 2000 → Oct 2001 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00065130 | Apr 2000 → Dec 2003 | gestational diabetes | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01520818 | Mar 2000 → Apr 2001 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00832182 | Dec 1999 → Nov 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01520753 | Mar → Jun 1999 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01467323 | Apr → Sep 1998 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01707134 | Sep 1997 → May 2000 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 454 trials | ||||||
| Phase 4 | NCT06127433 | Mar 2023 → May 2024 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT06739473 | Jan 2023 → Dec 2024 overdue | obesity disorder | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04834362 | Apr → Jun 2021 | hyperglycemia, stroke disorder | National Institute of Neurosciences and Hospital, Dhaka | Completed | No outcome recorded |
| Phase 4 | NCT04772729 | Mar 2021 → Mar 2023 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT04620967 | Feb 2021 → Jun 2022 | type 1 diabetes mellitus | Kirsten Nørgaard | Unknown | No outcome recorded |
| Phase 4 | NCT04538352 | Jan 2021 → Mar 2023 | type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04019821 | Jan 2020 → Jan 2023 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04012138 | Dec 2019 → Dec 2025 | — | Nantes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04157738 | Nov 2019 → Dec 2020 | type 1 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03554486 | Jul 2018 → Mar 2019 | type 1 diabetes mellitus | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03511521 | Mar 2018 → Aug 2019 | hyperglycemia | Northwestern University | Terminated | No outcome recorded |
| Phase 4 | NCT03328845 | Jan 2017 → Nov 2020 | type 1 diabetes mellitus | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Completed | No outcome recorded |
| Phase 4 | NCT02590016 | Sep 2015 → Dec 2020 | gestational diabetes | Tampere University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02453685 | Aug 2015 → Sep 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT03226210 | Feb 2015 → May 2016 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02276859 | Oct 2014 → Sep 2015 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04739241 | Jan 2014 → Apr 2018 | type 2 diabetes mellitus | Consorci Sanitari Integral | Completed | No outcome recorded |
| Phase 4 | NCT01648218 | Aug 2012 → Apr 2013 | — | Vancouver General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01654120 | Dec 2011 → Nov 2013 | type 2 diabetes mellitus | Mountain Diabetes and Endocrine Center | Completed | No outcome recorded |
| Phase 4 | NCT01486966 | Nov 2011 → Jun 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 4 | NCT01678235 | Sep 2011 → Sep 2012 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT01407289 | Jun 2011 → Apr 2012 | type 2 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT01333514 | Apr 2011 → Dec 2012 | type 2 diabetes mellitus | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01121835 | Feb 2010 → Mar 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01828970 | Jan 2010 → Sep 2012 | diabetes mellitus | Centre Europeen d'Etude du Diabete | Completed | No outcome recorded |
| Phase 4 | NCT00942318 | Mar 2009 → Feb 2013 | type 2 diabetes mellitus | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00807092 | Dec 2008 → Oct 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00657943 | Apr 2008 → Dec 2012 | atherosclerosis, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00607087 | Jan 2008 → Jun 2009 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00564395 | Aug 2007 → Dec 2009 | type 1 diabetes mellitus | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00998335 | Jun 2007 → Feb 2010 | type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00771693 | May 2007 → Jul 2011 | hyperglycemia, type 2 diabetes mellitus | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00346996 | May 2007 → Nov 2011 | type 1 diabetes mellitus | Lise Tarnow | Completed | No outcome recorded |
| Phase 4 | NCT00449839 | Apr 2007 → Oct 2008 | diabetes mellitus | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00590226 | Dec 2006 → Jan 2008 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00282451 | Feb → Aug 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01486862 | Oct 2005 → Jul 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00274274 | Sep 2005 → Nov 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00254085 | Mar 2005 → Mar 2006 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT00494988 | Dec 2004 → Apr 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00145353 | Nov 2004 → Jun 2006 | type 1 diabetes mellitus | Odense University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00095446 | Jul 2004 → Mar 2005 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00593255 | Jul 2004 → Apr 2005 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00571935 | Aug 2003 → Oct 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00572806 | Feb 2003 → Feb 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00121966 | Jan 2003 → Jul 2007 | type 2 diabetes mellitus | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00597233 | Oct → Dec 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00365170 | Sep 2002 → Apr 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01697631 | Jul 2002 → Apr 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01467141 | Jun 2002 → Oct 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01487798 | Jun 2002 → Nov 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01649570 | Mar 2002 → Aug 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00676819 | Jan → Jul 2002 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00663624 | — | diabetes mellitus | Emory University | Withdrawn | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07652528 | Aug 2026 → Jun 2028 expected | glucose metabolism disease, sudden sensorineural hearing loss | Hallym University | Not yet recruiting | No outcome recorded |
| — | NCT05199714 | Feb 2022 → Mar 2023 | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| — | NCT04200313 | Mar 2020 → Oct 2021 | type 1 diabetes mellitus | Jaeb Center for Health Research | Completed | No outcome recorded |
| — | NCT04184466 | Oct → Dec 2018 | — | Geropharm | Completed | No outcome recorded |
| — | NCT02518022 | Sep 2015 → Jun 2016 | hypoglycemia, type 1 diabetes mellitus | Kinderkrankenhaus auf der Bult | Withdrawn | No outcome recorded |
| — | NCT02419859 | Feb → Nov 2015 | type 2 diabetes mellitus | CeQur Corporation | Completed | No outcome recorded |
| — | NCT02144441 | Jun → Oct 2014 | diabetes mellitus | University of Pennsylvania | Withdrawn | No outcome recorded |
| — | NCT01947556 | Mar → Nov 2014 | diabetes mellitus | University Medical Center Nijmegen | Completed | No outcome recorded |
| — | NCT01974544 | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT01149005 | Jun 2010 → Jun 2015 | cystic fibrosis, glucose intolerance, lung disorder | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01088451 | Dec 2009 → Mar 2010 | type 1 diabetes mellitus | University Hospital Hradec Kralove | Unknown | No outcome recorded |
| — | NCT01588743 | Oct 2008 → Dec 2012 | type 2 diabetes mellitus | Li Guangwei | Unknown | No outcome recorded |
| — | NCT00625781 | Feb 2008 → Jun 2012 | glucose intolerance, macrosomia adiposa congenita | Region Örebro County | Completed | No outcome recorded |
| — | NCT00353431 | Dec 2006 → Apr 2010 | hyperglycemia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT00283218 | Jan → Aug 2006 | type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00464854 | Jul 2005 → Sep 2006 | diabetes mellitus | Assaf-Harofeh Medical Center | Terminated | No outcome recorded |
| — | NCT00410033 | Dec 1989 → May 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 188 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 127 trials | ||||||
| Phase 1 | NCT05104424 Comparator | Dec 2021 → Aug 2022 | olfactory nerve disorder, oral sensibility, disturbance of | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 1 | NCT04698018 Comparator | Apr 2021 → Jul 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03449433 Comparator | Mar → Aug 2018 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03179332 Comparator | Jun → Sep 2017 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02938572 Comparator | Oct 2016 → Jun 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02933853 Comparator | Oct 2016 → Dec 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02612844 Background | Nov 2015 → Jun 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02568280 Comparator | Oct 2015 → Apr 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02269735 Background | Nov 2014 → Jul 2016 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02131246 Comparator | May → Jul 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02059174 Background | Feb 2014 → Mar 2015 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02035371 Comparator | Jan → Jul 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02033239 Comparator | Jan → Jun 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02003677 Comparator | Nov 2013 → Aug 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01924637 Comparator | Aug → Nov 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03202875 Comparator | Nov → Dec 2012 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01682902 Comparator | Sep 2012 → Mar 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01618188 Comparator | Jun → Sep 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01469143 Comparator | Nov 2011 → Jan 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01296438 Comparator | Feb → Mar 2011 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01275131 Comparator | Jan → Dec 2011 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01121289 Comparator | Apr → Jul 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01028404 Background | Nov 2009 → Jun 2010 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00992537 Comparator | Oct 2009 → Jan 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00969592 Comparator | Nov → Dec 2007 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00652288 Comparator | Apr 2007 → Sep 2011 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01520831 Comparator | Apr 1999 → May 2000 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03981627 Comparator | Jun 2019 → Jun 2020 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1/2 | NCT02212951 Comparator | May → Jul 2014 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 1/2 | NCT02324309 Comparator | May → Nov 2014 | diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT06558708 Background | Jun → Dec 2024 overdue | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Recruiting | No outcome recorded |
| Phase 2 | NCT02846831 Comparator | Jan 2019 → Jan 2020 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02488616 Comparator | Mar → Nov 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02490098 Comparator | Jan → Jul 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT02855307 Comparator | Sep 2016 → Dec 2018 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02798250 Comparator | Jun 2016 → Mar 2017 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02626936 Comparator | Jan → Jun 2016 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02416765 Comparator | May → Oct 2015 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00850161 Comparator | Jul → Aug 2009 | type 1 diabetes mellitus | CPEX Pharmaceuticals Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00841087 Background | Jan → May 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00797823 Background | Nov 2008 → Sep 2009 | type 1 diabetes mellitus | Legacy Health System | Completed | No outcome recorded |
| Phase 2 | NCT00624767 Comparator | Mar → Apr 2008 | type 2 diabetes mellitus | Nastech Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00612040 Background | Jan → Jun 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02846857 Comparator | ? → Jul 2019 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07560150 Comparator | Apr → Jun 2026 overdue | — | Amphastar Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05539872 Comparator | Aug 2022 → Jan 2023 | — | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03430856 Comparator | Dec 2017 → Feb 2019 | type 2 diabetes mellitus | Biocon Limited | Completed | No outcome recorded |
| Phase 357 trials | ||||||
| Phase 3 | NCT07076199 Background | Aug 2025 → Jan 2027 expected | type 1 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT05767255 Comparator | Dec 2022 → Aug 2023 | type 2 diabetes mellitus | Hospital Universitario San Ignacio | Unknown | No outcome recorded |
| Phase 3 | NCT05013229 Comparator | Nov 2021 → Nov 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04974528 Comparator | Sep 2021 → Oct 2024 | type 1 diabetes mellitus, type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04880850 Background | May 2021 → Jun 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04848480 Background | Apr 2021 → Apr 2022 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04588259 Comparator | Oct 2020 → Jul 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03770767 Comparator | Nov 2019 → Mar 2023 | diabetes mellitus, pregnancy disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT03737240 Comparator | Jan 2019 → Jul 2022 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT03760068 Comparator | Nov 2018 → Dec 2019 | type 1 diabetes mellitus | Mylan Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03689374 Comparator | Oct 2018 → Feb 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03377699 Background | Nov 2017 → Dec 2020 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03268005 Comparator | Sep 2017 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03211858 Comparator | Aug 2017 → Jul 2018 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02906917 Comparator | Sep 2016 → Aug 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02825251 Comparator | Jul 2016 → Jun 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02670915 Comparator | May 2016 → Feb 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02420262 Comparator | Jul 2015 → Oct 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02100475 Comparator | Apr 2014 → Apr 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02034513 Background | Jan 2014 → Jan 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01999322 Comparator | Nov 2013 → May 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01835431 Background | Oct 2013 → Nov 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01831765 Comparator | Aug 2013 → May 2015 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01513473 Background | Jan 2012 → Jul 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01474538 Comparator | Dec 2011 → Feb 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01445951 Comparator | Sep 2011 → May 2013 | type 1 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01134107 Comparator | Nov 2010 → Dec 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01196104 Comparator | Sep 2010 → Aug 2011 | type 2 diabetes mellitus | Mannkind Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01109316 Comparator | Apr 2010 → Aug 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01079234 Background | Mar → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01074268 Background | Feb → Dec 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00972283 Background | Sep 2009 → Oct 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00982228 Background | Sep 2009 → Nov 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00978627 Background | Aug 2009 → May 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00623194 Background | Feb 2008 → Sep 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00523042 Comparator | Aug 2007 → Feb 2008 | asthma, type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00472953 Comparator | May 2007 → Mar 2008 | chronic obstructive pulmonary disease, type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00474045 Background | May 2007 → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00447382 Background | Mar 2007 → Jul 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00435019 Background | Feb 2007 → Sep 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00434954 Comparator | Feb 2007 → Jun 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00331604 Comparator | Aug 2006 → May 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00322257 Comparator | May 2006 → Apr 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00309244 Comparator | Feb 2006 → Aug 2008 | type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00504673 Background | Apr 2005 → Dec 2006 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00106366 Background | Mar → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00184600 Comparator | Nov 2004 → Aug 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00174668 Comparator | Nov 2004 → Nov 2007 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00095082 Background | Sep 2004 → Dec 2005 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00097084 Background | Sep 2004 → Dec 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00184665 Background | Jun 2004 → Sep 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00595374 Background | Dec 2003 → Oct 2004 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00312156 Background | Aug 2002 → Aug 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00312104 Background | Apr 2002 → Mar 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01697657 Background | Sep 2001 → Nov 2002 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00072904 Comparator | Jun 2001 → Dec 2007 | cystic fibrosis, diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 458 trials | ||||||
| Phase 4 | NCT07173712 Comparator | Mar 2026 → Jun 2027 expected | type 2 diabetes mellitus | Yanbing Li | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04381429 Comparator | Aug 2020 → Jan 2025 | cystic fibrosis-related diabetes | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 4 | NCT04416269 Background | Aug 2020 → Mar 2026 overdue | diabetes mellitus | Emory University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03987191 Background | Jan → Oct 2020 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT04124302 Background | Oct 2019 → Mar 2024 | type 1 diabetes mellitus | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT04120623 Comparator | Oct → Dec 2019 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03659799 Comparator | Apr 2019 → Dec 2022 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03660553 Comparator | Oct 2018 → Jun 2022 | type 2 diabetes mellitus | University of Miami | Terminated | No outcome recorded |
| Phase 4 | NCT04409587 Comparator | Apr 2018 → May 2020 | type 1 diabetes mellitus | Mountain Diabetes and Endocrine Center | Completed | No outcome recorded |
| Phase 4 | NCT03336528 Background | Jan 2018 → Mar 2021 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03260868 Background | Sep 2017 → Nov 2018 | type 1 diabetes mellitus | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT03824002 Background | Apr → Oct 2017 | type 2 diabetes mellitus | University of Palermo | Completed | No outcome recorded |
| Phase 4 | NCT02811484 Background | Jun 2016 → Jun 2018 | type 2 diabetes mellitus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02741687 Background | Jun 2016 → Apr 2017 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02688933 Background | May 2016 → Jun 2017 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02680054 Comparator | Feb 2016 → Aug 2018 | type 1 diabetes mellitus | Oxford University Hospitals NHS Trust | Terminated | No outcome recorded |
| Phase 4 | NCT02685449 Comparator | Feb 2016 → Feb 2018 | type 1 diabetes mellitus | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT02443402 Background | Jan → Dec 2016 | coronary artery disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03463564 Comparator | Jan 2016 → Dec 2026 expected | type 1 diabetes mellitus | University of Campania Luigi Vanvitelli | Recruiting | No outcome recorded |
| Phase 4 | NCT03112538 Comparator | Jan 2016 → Dec 2018 | type 2 diabetes mellitus | Clinical Research Centre, Malaysia | Unknown | No outcome recorded |
| Phase 4 | NCT02556918 Background | Jan 2016 → Nov 2018 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02621489 Background | Dec 2015 → Aug 2022 | atherosclerosis, coronary restenosis, diabetes mellitus | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT02408120 Comparator | Oct 2015 → Dec 2019 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02192450 Comparator | Jan 2015 → Feb 2019 | hypoglycemia, type 1 diabetes mellitus | Nordsjaellands Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01966978 Comparator | Nov 2014 → Dec 2017 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02155374 Comparator | May 2014 → Dec 2015 | hyperglycemia | Slotervaart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02004366 Background | Jan 2014 → Feb 2017 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01845831 Comparator | Aug 2013 → Apr 2016 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02219750 Comparator | Aug 2013 → Aug 2015 | type 2 diabetes mellitus | Mackay Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01848990 Background | Mar 2013 → Feb 2014 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01524705 Comparator | Aug 2012 → Jul 2014 | type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01526733 Background | Dec 2011 → Aug 2012 | type 1 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT01354925 Comparator | Sep 2011 | type 2 diabetes mellitus | Meir Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01417897 Comparator | Sep 2011 → May 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01269034 Comparator | Dec 2010 → Jan 2017 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01165684 Comparator | Oct 2010 → Apr 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01209403 Comparator | Sep 2010 → Jul 2011 | end stage renal failure | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01212913 Comparator | Aug 2010 → May 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01293396 Comparator | Jun 2010 → Feb 2011 | type 2 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT01101867 Comparator | Jun 2010 → Jun 2012 | diabetes mellitus | Kathleen Dungan | Completed | No outcome recorded |
| Phase 4 | NCT01068652 Comparator | Mar 2010 → May 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01269047 Comparator | Aug 2009 → Aug 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00965549 Comparator | Jul 2009 → Dec 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00913497 Comparator | Jun 2009 → Jan 2012 | type 1 diabetes mellitus | Corewell Health West | Completed | No outcome recorded |
| Phase 4 | NCT00906529 Comparator | May 2009 → Dec 2010 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT01211730 Comparator | Apr 2009 → Dec 2015 | hyperglycemia | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT00821795 Comparator | Mar 2009 → Apr 2013 | type 2 diabetes mellitus | Dennis G. Karounos, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00591227 Comparator | May 2008 → Jul 2009 | type 2 diabetes mellitus | Rush University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00537303 Comparator | Oct 2007 → Mar 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00542620 Comparator | Sep 2007 → Mar 2009 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00505882 Background | Jul 2007 → Dec 2008 | type 1 diabetes mellitus | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT00509925 Background | Jul 2007 → Jul 2008 | type 1 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 4 | NCT00467649 Comparator | May 2007 → Apr 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01271517 Comparator | Sep 2005 → Mar 2011 | type 1 diabetes mellitus | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT00117780 Background | Jun 2005 → Oct 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT00461331 Comparator | Oct 2004 → Jun 2007 | type 1 diabetes mellitus | Tulane University Health Sciences Center | Completed | No outcome recorded |
| Phase 4 | NCT00747409 Comparator | Jul 2004 → Mar 2009 | type 2 diabetes mellitus | Munich Municipal Hospital | Unknown | No outcome recorded |
| Phase not applicable26 trials | ||||||
| — | NCT07600944 Comparator | May → Aug 2026 overdue | — | Zhuhai United Laboratories Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT06532461 Comparator | Jul 2024 → Dec 2026 expected | type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Recruiting | No outcome recorded |
| — | NCT05417841 Comparator | Mar 2023 → Aug 2025 | type 2 diabetes mellitus | Beijing Hospital | Completed | No outcome recorded |
| — | NCT05221359 Background | May 2022 → Dec 2026 expected | type 1 diabetes mellitus | Defymed | Recruiting | No outcome recorded |
| — | NCT04243629 Background | Nov 2021 → Apr 2024 | hyperglycemia, type 1 diabetes mellitus | McGill University | Unknown | No outcome recorded |
| — | NCT04965051 Comparator | Aug 2021 → Dec 2023 | type 1 diabetes mellitus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT04853030 Comparator | Apr → Sep 2021 | type 1 diabetes mellitus | University of Ljubljana, Faculty of Medicine | Completed | No outcome recorded |
| — | NCT04031599 Comparator | Jul 2020 → Nov 2021 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| — | NCT04163874 Background | Feb 2020 → Jan 2022 | hyperglycemia, type 1 diabetes mellitus | McGill University | Completed | No outcome recorded |
| — | NCT03987308 Comparator | Jul 2019 → Sep 2025 overdue | diabetes mellitus, noninsulin-dependent, 2 | Beijing Hospital | Recruiting | No outcome recorded |
| — | NCT03993366 Background | Mar → Aug 2019 | type 1 diabetes mellitus | McGill University | Completed | No outcome recorded |
| — | NCT03212950 Comparator | Jul → Nov 2017 | type 1 diabetes mellitus | University of Ljubljana, Faculty of Medicine | Completed | No outcome recorded |
| — | NCT02887625 Comparator | Feb 2015 → May 2017 | type 2 diabetes mellitus | Dr. Muhammad Abdulghani | Unknown | No outcome recorded |
| — | NCT02824510 Comparator | Aug 2014 → Sep 2016 | type 1 diabetes mellitus | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT02155023 Background | Jan 2014 → Jan 2015 | diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT02006836 Background | Jan → Dec 2013 | type 2 diabetes mellitus | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT01643382 Comparator | Aug 2012 → Aug 2014 | diabetes mellitus, end stage renal failure | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01702311 Comparator | May 2012 → Dec 2013 | diabetes mellitus | Emory University | Completed | No outcome recorded |
| — | NCT01621776 Comparator | Jun 2011 → Aug 2012 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT01022658 Comparator | Jan 2010 → Jul 2011 | type 2 diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT01223560 Background | Oct 2009 → May 2010 | type 1 diabetes mellitus | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT00626080 Background | Jan 2009 → Dec 2011 | type 1 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT00428207 Comparator | Feb 2007 → Aug 2008 | type 1 diabetes mellitus | Joslin Diabetes Center | Terminated | No outcome recorded |
| — | NCT00494078 Comparator | Jun 2006 → Aug 2008 | critical illness polyneuropathy | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00574405 Comparator | Apr 2005 → Mar 2010 | type 1 diabetes mellitus | Arkansas Children's Hospital Research Institute | Completed | No outcome recorded |
| — | NCT00920725 Comparator | Jan 2005 → Jul 2007 | diabetic ketoacidosis | Rush University Medical Center | Completed | No outcome recorded |
Press releases naming this drug 36 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | Novo Nordisk A/S | COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisks nye hurtigtvirkende måltidsinsulin, Fiasp®, godkendt i USA novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk genindsender registreringsansøgningen for hurtigtvirkende insulin aspart i USA novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (fast-acting insulin aspart) approved in Europe novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes novonordisk.com ↗ |
| 2016-10-07 | Novo Nordisk A/S | Novo Nordisk modtager Complete Response Letter i USA vedrørende hurtigerevirkende insulin aspart novonordisk.com ↗ |
| 2016-10-07 | Novo Nordisk A/S | Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart novonordisk.com ↗ |
| 2015-12-09 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i USA til behandling af type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-12-09 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes novonordisk.com ↗ |
| 2015-12-04 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i EU til behandling af type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-12-04 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes novonordisk.com ↗ |
| 2015-03-25 | Novo Nordisk A/S | Novo Nordisk A/S : Novo Nordisk afslutter fase 3a-studier, der sammenligner hurtigerevirkende insulin aspart med NovoRapid® i type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-03-25 | Novo Nordisk A/S | Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes novonordisk.com ↗ |
| 2013-01-21 | Novo Nordisk A/S | Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) approved in Japan novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Positiv afstemning i FDA's rådgivende komite vedrørende godkendelse af insulin degludec og insulin degludec/ insulin aspart novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months novonordisk.com ↗ |
Evidence & citations 48 cited values
Every value below carries the sentence it was read from. 406 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin aspart | “Brain responses to viewing food and non-food pictures were measured using functional Magnetic Resonance Imaging in 32 type 1 diabetic patients, after each of two 12-week...” PMID 24739875 ↗ Apr 2014262“This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP®) versus insulin aspart...” PMID 33090016 ↗ Mar 2021 “Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in...” NCT02059174 ↗ “The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and...” PMID 33837106 ↗ Apr 2021 “This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard...” NCT05754424 ↗ “We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young...” PMID 31575640 ↗ Oct 2019 “This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T1DM comparing the efficacy and safety of GP40071 (insulin aspart, GEROPHARM)...” NCT04079413 ↗ “Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal.” NCT02680054 ↗ “Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.” NCT05013229 ↗ “We aimed to assess the efficacy of a novel faster-acting insulin aspart (Fiasp) plus pramlintide fully closed-loop system that does not require meal input.” PMID 34580055 ↗ Sep 2021 “Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening.” NCT02688933 ↗ “Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.” NCT04772729 ↗ “30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico” NCT01121835 ↗ “Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.” NCT04974528 ↗ “Diluted insulin U25 will be formulated by adding diluent, which will be obtained from Novo Nordisk, with insulin aspart.” NCT03666065 ↗ “receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care” PMID 36170500 ↗ Sep 2022 “Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese” NCT01620450 ↗ “Role of Insulin Aspart and Detemir to Assess Glucose Excursion in Children With Type 1 Diabetes” NCT00564395 ↗ “Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.” NCT01088451 ↗ “Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy” NCT03554486 ↗ “iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)” NCT03565666 ↗ “Single subcutaneous administration of Fiasp® (insulin aspart)” NCT03179332 ↗ “NPH (70%) plus regular insulin or insulin aspart (30%)” NCT00174668 ↗ “the insulin for CSII was insulin aspart(NovoRapid).” NCT02006836 ↗ “Subcutaneous injection of insulin aspart” NCT03981627 ↗ “Concentrated rapid acting insulin aspart” NCT04660305 ↗ “rapid acting Novorapid (insulin aspart)” NCT01271517 ↗ “premix of insulin aspart (NovoMix70)” NCT01354925 ↗ “insulin aspart (NovoRapid, NovoLog)” NCT00000620 ↗ “Insulin Aspart and Insulin Glargine” NCT04834362 ↗ “biphasic insulin aspart 50%” NCT04739241 ↗ “Insulin Aspart (NovoLog®)” NCT00071448 ↗ “insulin aspart(NovoRapid)” NCT02219750 ↗ “Drug: insulin aspart” NCT00612040 ↗ “Insulin aspart” NCT04079413 ↗ “insulin aspart” NCT00542620 ↗ |
| Known as | aspart | “Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or...” NCT03463564 ↗35“CONCLUSIONS: Long-term treatment with the insulin analogues detemir + aspart was superior to NPH + aspart in reducing HbA(1c), with added benefits of less major and nocturnal...” PMID 18387078 ↗ Apr 2008 “Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart)” NCT03112538 ↗ “Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed” NCT01845831 ↗ “The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day)” NCT04196231 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump.” NCT02855307 ↗ “Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved.” NCT01974544 ↗ “three randomly assigned insulin analog regimens (Detemir, Aspart, and their combination)” PMID 28954218 ↗ Sep 2017 “different insulin types (aspart vs ultra-rapid aspart) on hypoglycaemic risk.” PMID 39069599 ↗ Jul 2024 “rapid-acting insulin (lispro or aspart) before meals” NCT02004366 ↗ “Supplemental (correction) lispro or aspart insulin” NCT04416269 ↗ “Prandial Insulins (aspart, glulisine or lispro).” NCT01524705 ↗ “Subcutaneous insulin (aspart, glargine, detemir)” NCT00764556 ↗ “rapid acting insulin (aspart)” NCT00564395 ↗ “Lispro, Aspart, glulisine” NCT04157738 ↗ “insulin aspart (aspart)” PMID 36623517 ↗ Jan 2023 “Aspart” NCT04542148 ↗ |
| Known as | Aspart (Novolog) | “Aspart (Novolog)” NCT01702311 ↗ |
| Known as | aspart insulin | “A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)” NCT04381429 ↗ |
| Known as | BIAsp 30 | “a 30/70 (rapid/intermediate-acting) premixed suspension of the rapid-acting insulin analogue insulin aspart (BIAsp30) was compared with a similar premixed suspension of...” PMID 11009049 ↗ Aug 20001“BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin.” NCT00807092 ↗ |
| Known as | biphasic insulin aspart 30 | “BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin.” NCT00807092 ↗ |
| Known as | fast-acting insulin aspart | “The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin...” PMID 30547388 ↗ Dec 20189“A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without...” PMID 32209647 ↗ Mar 2020 “OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart...” PMID 28356319 ↗ Mar 2017 “Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than...” PMID 28205039 ↗ May 2017 “Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).” PMID 28345792 ↗ Jul 2017 “AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).” PMID 29493118 ↗ Mar 2018 “AIMS: To investigate the pharmacokinetic/pharmacodynamic properties of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D).” PMID 31069935 ↗ Jun 2019 “BACKGROUND: Fast-acting insulin aspart (faster aspart) is insulin aspart set in a new formulation with faster initial absorption after subcutaneous administration.” PMID 28185141 ↗ May 2017 “Ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), have pharmacokinetic properties” PMID 28918652 ↗ Sep 2017 “Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp).” PMID 30402720 ↗ May 2019 |
| Known as | faster acting Aspart | “faster acting Aspart (FiAsp) on glucose reduction during exercise.” NCT03659799 ↗ |
| Known as | faster aspart | “OBJECTIVE: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without...” PMID 32209647 ↗ Mar 202014“AIM: To evaluate the efficacy and safety of mealtime or post-meal fast-acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin...” PMID 30259644 ↗ Oct 2018 “OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart...” PMID 28356319 ↗ Mar 2017 “Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than...” PMID 28205039 ↗ May 2017 “AIM: To evaluate the pharmacological characteristics of faster-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp) during continuous subcutaneous insulin...” PMID 27709762 ↗ Nov 2016 “AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).” PMID 29493118 ↗ Mar 2018 “AIMS: To investigate the pharmacokinetic/pharmacodynamic properties of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D).” PMID 31069935 ↗ Jun 2019 “BACKGROUND: Fast-acting insulin aspart (faster aspart) is insulin aspart set in a new formulation with faster initial absorption after subcutaneous administration.” PMID 28185141 ↗ May 2017 “BACKGROUND: Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with additional excipients (L-arginine and niacinamide).” PMID 28165180 ↗ Feb 2017 “AIM: To confirm glycaemic control superiority of mealtime fast-acting insulin aspart (faster aspart) in a basal-bolus (BB) regimen vs basal-only insulin.” PMID 28345792 ↗ Jul 2017 “Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.” PMID 28483786 ↗ May 2017 “Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with faster absorption.” PMID 27873152 ↗ Jan 2017 “Ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), have pharmacokinetic properties” PMID 28918652 ↗ Sep 2017 “Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp).” PMID 30402720 ↗ May 2019 “faster-acting insulin aspart (faster aspart)” NCT03215498 ↗ |
| Known as | faster insulin aspart | “Participants were randomly assigned in a 1:1:1:1:1:1 ratio to a sequence of the three interventions, with faster insulin aspart used in all interventions.” PMID 38906614 ↗ Jul 2024 |
| Known as | faster-acting insulin aspart | “INTRODUCTION: Faster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in...” PMID 33837106 ↗ Apr 202122“The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in...” NCT01831765 ↗ “The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with...” NCT02033239 ↗ “Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with faster absorption.” PMID 27873152 ↗ Jan 2017 “Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)” NCT04853030 ↗ |
| Known as | Fiasp | “The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)...” NCT01924637 ↗21“This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp (faster-acting...” NCT02035371 ↗ “The aim of the trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of faster-acting insulin aspart (FIAsp) after different injection...” NCT02089451 ↗ “The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in...” NCT01831765 ↗ “The aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects...” NCT01850615 ↗ “The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with...” NCT02033239 ↗ “Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin” NCT03554486 ↗ “We aimed to assess the efficacy of a novel faster-acting insulin aspart (Fiasp) plus pramlintide fully closed-loop system that does not require meal input.” PMID 34580055 ↗ Sep 2021 “properties of FIAsp (faster-acting insulin aspart) and the currently marketed insulin aspart (NovoRapid®)” NCT01934712 ↗ “FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®)” NCT01992588 ↗ “faster acting Aspart (FiAsp) on glucose reduction during exercise.” NCT03659799 ↗ “Single subcutaneous administration of Fiasp® (insulin aspart)” NCT03179332 ↗ “Faster-acting insulin aspart (FIAsp)” NCT01819129 ↗ “FIAsp (faster-acting insulin aspart)” NCT01999322 ↗ |
| Known as | Gan & Lee Insulin Aspart | “A Glucose Clamp Trial Investigating The Biosimilarity of Gan & Lee Insulin Aspart Injection (Insulin Aspart 100 U/ml) With US and EU Insulin Aspart Comparator Products...” NCT04237129 ↗ |
| Known as | GL-Asp | “METHODS: Three phase 1, randomized, double-blind, three-period crossover trials compared single doses of the proposed biosimilar insulin analogues aspart (GL-Asp, n = 36),...” PMID 37735841 ↗ Sep 2023 |
| Known as | GP-Asp | “Aim: To compare safety and efficacy of GP40071 insulin aspart (GP-Asp) and NovoRapid® (NN-Asp).” PMID 33928797 ↗ Apr 2021 |
| Known as | GP40071 | “Aim: To compare safety and efficacy of GP40071 insulin aspart (GP-Asp) and NovoRapid® (NN-Asp).” PMID 33928797 ↗ Apr 2021 |
| Known as | Humulin kwickpen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02621489 ↗ |
| Known as | Humulin R U-500 | “A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin® R U-500 and Humalog® Mix75/25™ in Subjects With Type 2...” NCT02324309 ↗ |
| Known as | IAsp | “The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin...” PMID 30547388 ↗ Dec 201839“This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP®) versus insulin aspart...” PMID 33090016 ↗ Mar 2021 “OBJECTIVE: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without...” PMID 32209647 ↗ Mar 2020 “OBJECTIVES: Preprandial insulin injection in preschool children is complicated by irregular eating habits. Postprandial injection of rapid-acting insulin analogs such as...” PMID 17850471 ↗ Oct 2007 “Patients were randomized 1:1 (age stratified: 1-<6 years; 6-<12 years; 12-<18 years) to IDegAsp once daily (OD) plus insulin aspart (IAsp) for remaining meals (IDegAsp + IAsp),...” PMID 30014589 ↗ Aug 2018 “The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus...” PMID 17888133 ↗ Oct 2007 “AIM: To evaluate the efficacy and safety of mealtime or post-meal fast-acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin...” PMID 30259644 ↗ Oct 2018 “To evaluate efficacy and tolerability of a co-formulation of insulin degludec and insulin aspart (IDegAsp) with insulin aspart (IAsp) at other meals compared with basal-bolus...” PMID 22933438 ↗ Aug 2012 “AIM: Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification: addition of once-daily (OD) liraglutide (Lira)...” PMID 24443830 ↗ Feb 2014 “The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with...” NCT01697631 ↗ “OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart...” PMID 28356319 ↗ Mar 2017 “AIMS: To show that a thrice daily meal-time biphasic insulin aspart (BIAsp) treatment regimen is as efficacious as a 4 times daily basal-bolus regimen with human isophane...” PMID 17115349 ↗ Oct 2006 “Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than...” PMID 28205039 ↗ May 2017 “Type 2 diabetes patients on premixed insulin are commonly prescribed biphasic insulin with low prandial insulin content, such as biphasic insulin aspart (BIAsp) 30, comprising...” PMID 19049377 ↗ Dec 2008 “BACKGROUND: To study the long-term development (104 weeks) of insulin antibodies during treatment with insulin detemir (IDet) and insulin aspart (IAsp) in children with type 1...” PMID 27600385 ↗ Sep 2016 “BACKGROUND: Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin...” PMID 36352762 ↗ Nov 2022 “AIM: To evaluate the pharmacological characteristics of faster-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp) during continuous subcutaneous insulin...” PMID 27709762 ↗ Nov 2016 “Insulin aspart (IAsp) and its biphasic preparations BIAsp50 and BIAsp70 (containing 50% and 70% IAsp, respectively) have distinct glucose-lowering properties as compared to...” PMID 24725803 ↗ Apr 2014 “AIMS: To confirm non-inferiority of insulin degludec/insulin aspart (IDegAsp) once-daily (OD) versus insulin glargine (IGlar) U100 OD + insulin aspart (IAsp) OD for HbA1c after 26 weeks” PMID 30448451 ↗ Nov 2018 “AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).” PMID 29493118 ↗ Mar 2018 “OBJECTIVE: To assess the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes.” PMID 17392539 ↗ Apr 2007 “AIMS: To investigate the pharmacokinetic/pharmacodynamic properties of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D).” PMID 31069935 ↗ Jun 2019 “insulin degludec (IDeg) and insulin aspart (IAsp)--administered as a co-formulation (IDegAsp) or as a basal-bolus regimen (IDeg and IAsp in separate injections).” PMID 26592732 ↗ Jan 2016 “BACKGROUND: Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with additional excipients (L-arginine and niacinamide).” PMID 28165180 ↗ Feb 2017 “NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in subjects with type 1 diabetes mellitus.” NCT01173926 ↗ “The pharmacokinetics and pharmacodynamics of insulin aspart (IAsp) were studied in elderly patients to examine the potential for postprandial dosing.” PMID 19120432 ↗ Jan 2009 “fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII)” PMID 30537180 ↗ Jan 2019 “using either insulin aspart (IAsp) or human insulin (HI) in combination with Neutral Protamine Hagedorn (NPH) insulin” PMID 18644065 ↗ Jul 2008 “by either adding a once-daily (OD) bolus injection of insulin aspart (IAsp) or by switching to a basal-bolus regimen” PMID 27853981 ↗ Nov 2016 “Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp).” PMID 30402720 ↗ May 2019 “IDeg or IDet as OD basal insulin treatment combined with mealtime bolus insulin aspart (IAsp).” PMID 24702700 ↗ May 2014 “with separate bolus insulin aspart (IAsp) as needed for safety and glycemic control” PMID 24888255 ↗ Jun 2014 “rapid acting insulin analogue, insulin Aspart (IAsp)” PMID 19016075 ↗ 2008 “mealtime insulin aspart (IAsp) or human insulin (HI)” PMID 20388052 ↗ May 2010 “Insulin aspart (Iasp) in insulin pump” NCT04620967 ↗ “premeal insulin aspart (IAsp)” PMID 16842476 ↗ Jul 2006 “insulin aspart (IAsp)” PMID 11978684 ↗ May 2002 “insulin aspart (IAsp)” PMID 35546450 ↗ Jun 2022 “insulin aspart (IAsp)” NCT00992537 ↗ “insulin aspart (IAsp)” NCT00972283 ↗ |
| Known as | Insulin aspart (Novo Rapid, Novo Nordisk) | “Insulin aspart (Novo Rapid, Novo Nordisk)” NCT04772729 ↗ |
| Known as | insulin aspart (NovoRapid, NovoLog) | “insulin aspart (NovoRapid, NovoLog)” NCT00000620 ↗ |
| Known as | Insulin aspart - insulin Novolog | “Insulin aspart - insulin Novolog” NCT00461331 ↗ |
| Known as | Insulin aspart = Novolog (Novo Nordisk) | “Insulin aspart = Novolog (Novo Nordisk)” NCT00998335 ↗ |
| Known as | insulin aspart protamine/insulin aspart 70/30 mix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00821795 ↗ |
| Known as | Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00888732 ↗ |
| Known as | Insulin Aspart/NovoRapid | “Insulin Aspart/NovoRapid” NCT00449839 ↗ |
| Known as | Insulin Fiasp | “Insulin Fiasp” NCT03770767 ↗ |
| Known as | insulin levemir / aspart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00346996 ↗ |
| Known as | Insulin, Asp(B28)- | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00797823 ↗ |
| Known as | insuline asparte | “10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus” NCT04012138 ↗ |
| Known as | Intranasal Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00314314 ↗ |
| Known as | NN-Asp | “The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp)” PMID 33432547 ↗ Jan 20211“originator insulin aspart (100 U/mL; NN-Asp; NovoLog®)” PMID 31833801 ↗ Jan 2020 |
| Known as | NN1218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01121289 ↗ |
| Known as | Novo Rapid Insulin | “Novo Rapid Insulin (Novonordisk)” NCT01149005 ↗ |
| Known as | NovoLog | “This is a single-center randomized open label active-controlled crossover trial comparing efficacy and safety of fast acting insulin aspart (FA) (FIASP®) versus insulin aspart...” PMID 33090016 ↗ Mar 202129“The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose...” NCT00065130 ↗ “Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in...” NCT02059174 ↗ “An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring...” NCT00095446 ↗ “This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.” NCT00097071 ↗ “Participants can take very short acting insulin (e.g. Humalog or Novolog) up to 2 hours before the test if necessary and then that will be withheld during the test.” NCT01269047 ↗ “randomly assigned to receive a dose of 0-to-120 IU of NovoLog (Insulin Aspart) before being randomized to 20 min of exercise or sitting control condition” PMID 33856613 ↗ Apr 2021 “rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])” NCT00467649 ↗ “United States-sourced insulin aspart (NovoLog®), and European Union-sourced insulin aspart (NovoRapid®)” PMID 31825248 ↗ Dec 2019 “originator insulin aspart (100 U/mL; NN-Asp; NovoLog®)” PMID 31833801 ↗ Jan 2020 “Insulin (Aspart Insulin [Novolog], Regular Insulin)” NCT00920725 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “Lantus, Levemir, Novolog, Lispro” NCT02811484 ↗ “Insulin Aspart (NovoLog®)” NCT00071448 ↗ “Insulin aspart (NovoLog®)” NCT01682902 ↗ “Novolog/ Humalog” NCT01269034 ↗ “(NovoLog®)” NCT00913497 ↗ “Novolog” NCT01654120 ↗ |
| Known as | novolog insulin | “Drug: novolog insulin” NCT02496780 ↗ |
| Known as | NovoLog Insulin aspart | “NovoLog Insulin aspart” NCT04292535 ↗ |
| Known as | NovoLog/NovoRapid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03211858 ↗ |
| Known as | NovoMix70 | “premix of insulin aspart (NovoMix70)” NCT01354925 ↗ |
| Known as | Novorapid | “In a randomized cross-over study, 11 non-diabetic HD patients received a standardised HD session with either: 1) no treatment, 2) glucose infusion (10% glucose, 2.5 mL/kg/h),...” PMID 23557110 ↗ Apr 201347“A Single Centre, Randomized, Balanced Double Blind, Cross-Over Trial Investigating the Bioequivalence of NovoRapid® Produced by the Current Process and Insulin Aspart With the...” NCT01486914 ↗ “The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and...” PMID 33837106 ↗ Apr 2021 “Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.” NCT04772729 ↗ “Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min)” NCT06739473 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “Participants will either get faster aspart or insulin aspart (NovoRapid®) - which treatment is decided by chance.” NCT04588259 ↗ “insulin aspart (NovoRapid®) given as a bolus on top of a basal continuous subcutaneous insulin infusion (CSII).” NCT01992588 ↗ “An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.” NCT03407599 ↗ “United States-sourced insulin aspart (NovoLog®), and European Union-sourced insulin aspart (NovoRapid®)” PMID 31825248 ↗ Dec 2019 “Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen” NCT00365170 ↗ “Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.” NCT01088451 ↗ “Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day” NCT02491528 ↗ “Single subcutaneous administration of Novorapid® (insulin aspart)” NCT03179332 ↗ “the currently marketed formulation of insulin aspart (NovoRapid®)” NCT03215498 ↗ “Novorapid or Humalog insulin delivered in a basal-bolus manner.” NCT04243629 ↗ “NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark)” NCT03226210 ↗ “Meal-time NovoRapid® (insulin aspart) and insulin degludec” NCT02670915 ↗ “compared to the reference product called NovoRapid®.” NCT04698018 ↗ “Insulin rapid acting analog (Humalog\*, Novorapid\*)” NCT01756105 ↗ “NovoRapid® (insulin aspart) as meal time insulin” NCT01649570 ↗ “currently marketed insulin aspart (NovoRapid®)” NCT01934712 ↗ “rapid acting Novorapid (insulin aspart)” NCT01271517 ↗ “Insulin Aspart Injection（NovoRapid®）” NCT07600944 ↗ “Insulin aspart (Novorapid®)” NCT00771693 ↗ “Insulin Aspart (NovoRapid®)” NCT00593255 ↗ “insulin aspart (NovoRapid®)” NCT01999322 ↗ “insulin aspart(NovoRapid)” NCT02219750 ↗ “Novorapid (NovoNordisk)” NCT00494078 ↗ “Novorapid or Humalog” NCT02518022 ↗ “Novorapid” NCT02155023 ↗ |
| Known as | PIA | “premixed insulin aspart 70/30 BID (PIA)” PMID 21285388 ↗ Feb 2011 |
| Known as | rapilin | “Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced...” PMID 37735841 ↗ Sep 2023 |
| Known as | Sliding scale insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02155374 ↗ |
| Known as | Standard acting insulin Aspart | “Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid” NCT04853030 ↗ |
| Known as | UBLIN | “Insulin Aspart Injection（UBLIN®）” NCT07600944 ↗ |
| Known as | X14 | “An Open-labelled, Controlled, Multicentre, Multinational, Extension Study Assessing Safety and Efficacy of the Human Insulin Analogue Insulin Aspart (X14) and Human Soluble...” NCT01707134 ↗ |
| Modality | Protein / enzyme biologic | “The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus...” PMID 17888133 ↗ Oct 2007 |
| Route | Subcutaneous | “External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart” NCT00095446 ↗ |